Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Phosphate Therapeutics
With
Clinipace Worldwide
PT20 represents a mechanism to address many of the limitations associated with current phosphate binding agents. The available clinical and non clinical evidence suggests that PT20 binds phosphate and prevents its uptake more efficiently than other phosphate binding drugs and may therefore either reduce the pill burden associated with controlling phosphate levels, or result in lower phosphate levels with the same pill burden.
The this study is the first to investigate the efficacy and safety of PT20 in subjects with dialysis-dependent chronic kidney disease (CKD).
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women aged 18 90 years
Subject must have a stable dialysis prescription for at least 28 days prior to start of Screening.
Subject must have the most recent serum phosphate measurement, taken during the 28 days prior to the start of Screening, of ≥ 4.0 mg/dL and ≤ 8 mg/dL.
You may not be if
Subject's most recent historical pre-dialysis serum bicarbonate value within 14 days prior to the start of Screening (Visit 1) is \< 18 mg/dL.
Subject has, in the opinion of the investigator, severe chronic lung disease and/or carbon dioxide retention.
